Obsidian’s CAR controls

Why investors flocked to a $49.5M series A round for CAR T play Obsidian

Obsidian Therapeutics Inc. had no trouble attracting investors to its $49.5 million in series A round after it generated a preclinical pipeline of CAR T therapies with tunable activity.

GV led the round and was joined by fellow new investors Takeda Ventures Inc., Vertex

Read the full 444 word article

User Sign In